In this line, it has been demonstrated that topoisomerase I (Top-1) inhibitor irinotecan (MM-398) is able to increase the sensitivity of melanoma cell lines from patients to autologous T cell-mediated cytotoxicity. This evidence concerns the gene TOP1 and melanoma.